Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
MEMANTINE, AMANTADINE, AND L-DEPRENYL POTENTIATE THE ACTION OF L-DOPAIN MONOAMINE-DEPLETED RATS
Autore:
SKUZA G; ROGOZ Z; QUACK G; DANYSZ W;
Indirizzi:
MERZ&CO,POB 11 13 53 D-60048 FRANKFURT GERMANY MERZ&CO D-60048 FRANKFURT GERMANY PAN,INST PHARMACOL KRAKOW POLAND
Titolo Testata:
Journal of neural transmission
fascicolo: 1, volume: 98, anno: 1994,
pagine: 57 - 67
SICI:
0300-9564(1994)98:1<57:MAALPT>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTIPARKINSONIAN DRUGS MEMANTINE; NMDA RECEPTOR ANTAGONIST; D-ASPARTATE ANTAGONISTS; PARKINSONS-DISEASE; AGONISTS; RELEASE; NEUROTOXICITY; ACETYLCHOLINE; RESPONSES; TURNOVER;
Keywords:
LOCOMOTION; PARKINSONS MODEL; RESERPINE; ALPHA-METHYL-P-TYROSINE; MEMANTINE,; AMANTADINE; L-DEPRENYL; BROMOCRIPTINE; L-DOPA; SYNERGISM; RATS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
33
Recensione:
Indirizzi per estratti:
Citazione:
G. Skuza et al., "MEMANTINE, AMANTADINE, AND L-DEPRENYL POTENTIATE THE ACTION OF L-DOPAIN MONOAMINE-DEPLETED RATS", Journal of neural transmission, 98(1), 1994, pp. 57-67

Abstract

Some treatments used for Parkinson's disease attenuate locomotor depression in rats treated with reserpine and cr-methyl-p-tyrosine. In thepresent study memantine (2.5, 5.0 mg/kg), amantadine (10, 20 mg/kg) (both uncompetitive NMDA antagonists), and L-deprenyl (1.0, 5.0 mg/kg; MAO-B inhibitor) were tested for possible synergistic interactions with the dopamine agonists: bromocriptine (2.5, 5.0 mg/kg) and L-DOPA (50, 100 mg/kg, + benserazide, 100 mg/kg). At higher doses, memantine (10mg/kg), amantadine (40 mg/kg), bromocriptine (5 and 10 mg/kg) and L-DOPA (100, 200 mg/kg) but not L-deprenyl (up to 10 mg/kg) produced a pronounced increase in locomotor activity when given alone. The combination of memantine, amantadine and L-deprenyl with bromocriptine did notresult in synergism of action and, at best, an additive effect was seen. On the other hand the combination of these agents with L-DOPA produced a pronounced synergistic effect. Hence, the clinical observation that coadministration of L-DOPA with either memantine or amantadine results in enhancement of their action is also reflected in an animal model of Parkinson's disease. Such a combination therapy should allow the use of lower doses of both drugs which may reduce the occurrence of side effects and may also be predicted to have additional benefits related to the neuroprotective properties of memantine, amantadine, and L-deprenyl.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/21 alle ore 10:01:31